Gerald Chun-To So

Dr. Gerald Chun-To So

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
GSGerald Chun-To So
Gerald Chun-To So
JLJessica Bo Li Lu
Jessica Bo Li Lu
SKSachiko Koyama
Sachiko Koyama
YCYing‐Hua Cheng
Ying‐Hua Cheng
DGDebora L. Gisch
Debora L. Gisch
MEMichael Eadon
Michael Eadon
One in six Americans uses cannabidiol‐based or cannabis‐derived products. Cannabidiol is a substrate of CYP3A, but its role as a potential CYP3A inhibitor remains unclear. We hypothesized that cannabidiol would inhibit CYP3A‐mediated metabolism of tacrolimus. This report is an interim analysis of an open‐label, three‐period, fixed‐sequence, crossover study in healthy participants. Participants first received a single dose of tacrolimus 5 mg orally. After washout, participants later received cannabidiol titrated to 5 mg/kg twice daily for 14 days to reach a steady state, followed by a second single dose of tacrolimus 5 mg orally. Tacrolimus concentrations in whole blood were measured by UHPLC–MS/MS method. Pharmacokinetic parameters were calculated by noncompartmental analysis. Twelve participants completed all periods of the study. The maximum concentration (Cmax) of tacrolimus increased 4.2‐fold (P < 0.0001) with cannabidiol (40.2 ± 13.5 ng/mL) compared with without cannabidiol (9.85 ± 4.63 ng/mL). The area under the concentration‐vs.‐time curve (AUC0‐∞) increased 3.1‐fold (P < 0.0001). No change in half‐life (t1/2) was observed. This study demonstrates that cannabidiol increases tacrolimus exposure. Our data suggest the need for dose reduction in tacrolimus and frequent therapeutic dose monitoring in transplant patients taking cannabidiol concomitantly. Whether this observed interaction occurred due to the inhibition of CYP3A4 and/or CYP3A5 in the liver, intestine, or both, or intestinal drug transporters (e.g., p‐glycoprotein) during the first‐pass elimination remains to be elucidated.

7 February 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
GSGerald Chun-To So
Gerald Chun-To So
JLJessica Bo Li Lu
Jessica Bo Li Lu
YCYing‐Hua Cheng
Ying‐Hua Cheng
DGDebora L. Gisch
Debora L. Gisch
Sachiko KoyamaSachiko Koyama
Sachiko Koyama
MEMichael Eadon
Michael Eadon
Drug interactions are major causes of interindividual variability in tacrolimus exposure and effect. Tacrolimus, a widely used drug in transplant patients, is metabolized by CYP3A4 and CYP3A5. Cannabidiol (CBD) use after transplant is common. Clinical cases suggest CBD may alter tacrolimus exposure, but the mechanism of this interaction is unknown. We hypothesize that cannabidiol will inhibit tacrolimus metabolism in vitro mainly through CYP3A5 inhibition. In pooled human liver microsomes (HLMs) and recombinant (r) CYP3A4 and CYP3A5 enzymes, tacrolimus (1 μM) metabolism was determined using substrate depletion method in the absence (control) and the presence of 10 μM CBD, 7‐hydroxyCBD, and 7‐carboxyCBD. Ketoconazole (1 μM) served as a positive control for the inhibition of CYP3A. Linear regression analyses were performed to obtain kinetic parameters of the depletion. Tacrolimus depletion half‐life was 2.54, 0.922, and 0.351 min with pooled HLMs, rCYP3A4, and rCYP3A5, respectively. In pooled HLMs, CBD and 7‐hydroxyCBD increased tacrolimus half‐life by 0.8‐ and 2.3‐fold (both p < 0.0001), respectively. In rCYP3A4, CBD, 7‐hydroxyCBD, and ketoconazole prolonged tacrolimus half‐life by 5.8‐, 14‐, and 7.7‐fold, respectively. In rCYP3A5, CBD, 7‐hydroxyCBD, and ketoconazole prolonged half‐life by 29.3‐, 19.7‐, and 0.1‐fold, respectively. In all experiments, 7‐carboxyCBD had minimal effect on tacrolimus depletion. CBD and 7‐hydroxyCBD inhibited tacrolimus metabolism in vitro. CBD showed stronger inhibition in rCYP3A5 than rCYP3A4. The demonstrated CYP3A5 selectivity of cannabidiol may contribute to the in vitro identification of CYP3A5 substrates in new drug development. Our results support the potential of a clinical drug–drug interaction between CBD and tacrolimus.

Verified
Journal Article
Open access
PDF file
Sachiko KoyamaSachiko Koyama
Sachiko Koyama
JEJumar Etkins
Jumar Etkins
JJJoshua Jun
Joshua Jun
MMMatthew Miller
Matthew Miller
GSGerald Chun-To So
Gerald Chun-To So
MEMichael Eadon
Michael Eadon
Cannabidiol (CBD) is one of the major phytochemical constituents of cannabis, Cannabis sativa, widely recognized for its therapeutic potential. While cannabis has been utilized for medicinal purposes since ancient times, its psychoactive and addictive properties led to its prohibition in 1937, with only the medical use being reauthorized in 1998. Unlike tetrahydrocannabinol (THC), CBD lacks psychoactive and addictive properties, yet the name that suggests its association with cannabis has significantly contributed to its public visibility. CBD exhibits diverse pharmacological properties, most notably anti-inflammatory effects. Additionally, it interacts with key drug-metabolizing enzyme families, including cytochrome P450 (CYP) and uridine 5′-diphospho-glucuronosyltransferase (UGT), which mediate phase I and phase II metabolism, respectively. By binding to these enzymes, CBD can inhibit the metabolism of co-administered drugs, which can potentially enhance their toxicity or therapeutic effects. Mild to moderate adverse events associated with CBD use have been reported. Advances in chemical formulation techniques have recently enabled strategies to minimize these effects. This review provides an overview of CBD, covering its historical background, recent clinical trials, adverse event profiles, and interactions with molecular targets such as receptors, channels, and enzymes. We particularly emphasize the mechanisms underlying its anti-inflammatory effects and interaction with drugs relevant to organ transplantation. Finally, we explore recent progress in the chemical formulation of CBD in order to enhance its bioavailability, which will enable decreasing the dose to use and increase its safety and efficacy.

23 February 2026 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
XLXiaofu Liu
Xiaofu Liu
ASAditi Shendre
Aditi Shendre
LWLei Wang
Lei Wang
AOAislinn O'KAne
Aislinn O'KAne
HMHanson Ma
Hanson Ma
LLLiang Li
Liang Li
Pregnant women and children have been underrepresented in clinical studies due to ethical concerns and perceived vulnerabilities. This resulted in a significant gap in knowledge regarding the safety and efficacy of medications for these populations. Maternal and Pediatric PRecision In Therapeutics Knowledge Portal (MPRINT‐KP) is designed to provide a comprehensive view of pharmacokinetic, pharmaco‐epidemiology, and clinical trial research evidence in maternal and pediatric patient populations. MPRINT‐KP Silver was generated upon BioBERT models, due to their supreme performance in classifying pharmacokinetic, pharmaco‐epidemiology, and clinical trial papers from PubMed, with an F1‐score > 0.91. As of April 1, 2025, MPRINT‐KP Silver contains 758,560 clinical pharmacology research papers in maternal and pediatric populations. The landscape analysis revealed a large number of drugs with pharmacology knowledge gaps, which is calculated as the relative frequency of drugs with no or weak (i.e., less than five publications) evidence in each of pharmacokinetic, pharmaco‐epidemiology, or clinical trial study type. The highest pharmacotherapy knowledge gaps are in postpartum women, pregnant women, and pediatric patients between 0–12 and 12–18 years of age (51.37%, 32.47%, 25.82%, 32.11%, respectively). Pharmacovigilance analyses were conducted on highly prescribed drugs with limited pharmacology evidence in pediatric patients 0–2 year old and pregnant women using United States Food and Drug Administration Adverse Event Reporting System (FAERS) and MarketScan claims data. A number of new drug‐associated adverse drug events (ADEs) were discovered. In pediatric patients, there were crisaborole‐associated hemorrhage and moxifloxacin‐associated cardiac toxicities. In pregnant women, the analysis revealed terconazole‐associated abnormalities of heartbeat; benzonatate‐associated depressive and anxiety disorders; buspirone‐associated abnormalities of heartbeat; cyclobenzaprine‐associated tubulo‐interstitial nephritis; and pantoprazole‐associated hearing loss and voice and resonance disorders. For the first time, a large‐scale landscape analysis of pharmacotherapy knowledge gap in both maternal and pediatric patient populations was conducted and identified new drug associated ADE evidence using real world data.

26 December 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
JEJumar Etkins
Jumar Etkins
GSGerald Chun-To So
Gerald Chun-To So
JLJessica Bo Li Lu
Jessica Bo Li Lu
Sachiko KoyamaSachiko Koyama
Sachiko Koyama
DGDebora L. Gisch
Debora L. Gisch
MEMichael Eadon
Michael Eadon
Cannabidiol (CBD) use has increased in America due to its widespread availability. Cannabidiol is metabolized by multiple polymorphic enzymes including CYP3A, CYP2C9, and CYP2C19. We sought to evaluate the genotype‐specific adverse events and pharmacokinetic profiles of cannabidiol, 7‐OH cannabidiol (an active metabolite), and 7‐COOH cannabidiol. We completed a secondary analysis of an open‐label, fixed‐sequence, single‐center study of cannabidiol in 33 healthy subjects. Patients first received a single dose of cannabidiol 5 mg/kg orally with serial plasma concentrations measured. Later, patients were titrated to 5 mg/kg twice daily for 14 days to reach steady state with serial plasma concentrations measured. CYP3A, CYP2C9, and CYP2C19 genotypes were assessed. Pharmacokinetic parameters were calculated by noncompartmental analysis. Diarrhea was observed more frequently in individuals with both CYP3A5 poor metabolism and CYP2C19 intermediate/normal metabolism (39%) compared to individuals with other genotypes (7%, p = 0.0463). Individuals with both CYP3A5 poor metabolism and CYP2C19 intermediate/normal metabolism had increased 7‐OH cannabidiol and 7‐COOH cannabidiol exposure at steady state. Cannabidiol parent drug exposure varied by CYP2C19 metabolizer status, with lower cannabidiol exposure and parent to metabolite ratios in intermediate metabolizers after single dose ( p = 0.014) and at steady state ( p = 0.0033). Similar CYP2C19 genotype‐specific exposure was observed in an external validation cohort. Minor differences in exposure of cannabidiol and its metabolites were observed between CYP3A5 and CYP2C9 genotype groups. Significant changes in pharmacokinetics were observed between CYP2C9, CYP2C19, and CYP3A5 genotype groups. Future studies should assess whether pharmacogenomics can predict intestinal concentrations of CBD, its metabolites, and diarrhea.

18 November 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
DGDebora L. Gisch
Debora L. Gisch
Sachiko KoyamaSachiko Koyama
Sachiko Koyama
JEJumar Etkins
Jumar Etkins
GSGerald Chun-To So
Gerald Chun-To So
DFDaniel J. Fehrenbach
Daniel J. Fehrenbach
MEMichael Eadon
Michael Eadon
BACKGROUND: Cannabidiol (CBD) is increasingly used for pain management, including in transplant recipients with limited analgesic options. Its immunomodulatory effects in humans are not well defined at a single-cell level at CBD steady state with concomitant tacrolimus treatment. METHODS: In a phase I ex vivo study, peripheral blood mononuclear cells from 23 participants who received oral CBD (Epidiolex) up to 5 mg/kg twice daily for 11 days were collected before CBD (pre-CBD) and at steady state (post-CBD). Lymphocytes were isolated and stimulated with anti-CD3/CD28 antibodies, with or without tacrolimus (5 ng/mL). Pharmacodynamic responses were assessed using CellTiter-Glo proliferation, single-cell and single-nucleus RNA sequencing, cytokine assays, and flow cytometry. Steady-state plasma concentrations of CBD were quantified via tandem mass spectrometry. RESULTS: We identified an increased proportion of T effector memory (TEM) cells post-CBD (22% increase), which correlated with CBD plasma concentrations ( R = 0.77, P = 0.01). CBD reduced proliferation of T (37% decrease) and CD70 hi B (17% decrease) lymphocytes with additive immunosuppressive effects to tacrolimus. Single-cell RNA sequencing revealed reduced IL2 and TNF signaling and altered receptor-ligand networks in TEM cells. Post-CBD cytokine assays revealed elevated proinflammatory IL-6 protein levels and antiinflammatory IL-10 levels, with reduced TNF-α, LTA, and IL-2. In flow cytometry, the proportion of TEM and TEMRA cells increased post-CBD with tacrolimus. CONCLUSION: CBD exerts mixed immunomodulatory effects in humans, combining antiproliferative and pro- and antiinflammatory responses. Understanding the clinical safety of CBD use is important given the paucity of pain control options available for immunocompromised transplant populations. TRIAL REGISTRATION: ClinicalTrials.gov NCT05490511 FUNDING: NIH/National Center for Complementary and Integrative Health (R01AT011463); NIH/National Institute of General Medical Sciences (NIGMS) (R35GM145383); Intramural Research Program of the NIH; NIH/NIGMS (T32GM008425).